NOVORAPID

This brand name is authorized in Nigeria. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug NOVORAPID contains one active pharmaceutical ingredient (API):

1	Insulin aspart UNII 978D8U419H - SACCHAROMYCES CEREVISIAE
	The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin aspart produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. Insulin aspart has a shorter duration of action compared to soluble human insulin after subcutaneous injection.
	Read more about Insulin aspart

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A6-0207	Solution for injection	NovoRapid FlexPen 100 units/mL Solution for Injection in Pre-Filled Pen INJ_SOL 100 IU/mL 3 mL x 5's (in pre-filled pen)	Solution for injection. The solution is clear, colourless and aqueous	28/09/2023

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NOVORAPID Solution for injection in vial / Cartridge / Pre-filled pen	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10AB05	Insulin aspart	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10A Insulins and analogues → A10AB Insulins and analogues for injection, fast-acting
Discover more medicines within A10AB05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	12254Y, 8435Y, 8571D
BR	Câmara de Regulação do Mercado de Medicamentos	526601401153416, 526601402151417, 526601801151410, 526601901156414
CA	Health Products and Food Branch	02244353, 02245397, 02377209
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	26.220-03-05, 26.468-06-05
EE	Ravimiamet	1045796, 1092541, 1214615, 1214637, 1214648, 1214671, 1214783, 1214794, 1351156, 1351167, 1591253, 1591264, 1591275, 1638288, 1710267
ES	Centro de información online de medicamentos de la AEMPS	199119003, 199119024, 99119001, 99119009
FI	Lääkealan turvallisuus- ja kehittämiskeskus	006102, 007523, 093948, 467931
FR	Base de données publique des médicaments	61232223, 62278832, 65918860, 69482353
GB	Medicines & Healthcare Products Regulatory Agency	143901, 146651, 146659, 195703, 262097, 32794, 32808, 32824, 376955, 376959, 379731, 379734
HK	Department of Health Drug Office	46862, 55341, 60321, 60462
IE	Health Products Regulatory Authority	62709, 62710, 62720, 62730, 63121, 73541
IL	מִשְׂרַד הַבְּרִיאוּת	4342, 4881, 6585
IT	Agenzia del Farmaco	034498016, 034498028, 034498030, 034498042, 034498055, 034498093, 034498131, 034498232, 034498244
JP	医薬品医療機器総合機構	2492415A2035, 2492415A3031, 2492415A4038, 2492415G1031, 2492415G2020, 2492415G3026, 2492415G4022, 2492415G5029, 2492415G6025
LT	Valstybinė vaistų kontrolės tarnyba	1004367, 1004368, 1010935, 1029912, 1029913, 1029914, 1029916, 1029917, 1029918, 1029919, 1038361, 1060181, 1060182, 1064168, 1064169, 1064170, 1064171, 1064172, 1075477, 1076734
NG	Registered Drug Product Database	A6-0207
NL	Z-Index G-Standaard	14305003, 14305054, 15068641
NL	Z-Index G-Standaard, PRK	121355, 121495, 53880, 53902
NZ	Medicines and Medical Devices Safety Authority	10732, 15621, 8563, 8564
PL	Rejestru Produktów Leczniczych	100090804, 100108898, 100305469, 100312073, 100312311, 100329671
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W07268001, W07268002, W08932001, W08932002, W08932003, W12152001, W12152002, W12152003, W52654001, W52654002, W52654003, W52655001, W52655002
SG	Health Sciences Authority	11394P, 12189P
TN	Direction de la Pharmacie et du Médicament	5993081
TR	İlaç ve Tıbbi Cihaz Kurumu	8699676770656, 8699676950669, 8699676950676
ZA	Health Products Regulatory Authority	34/21.1/0160